Yuya, M., Daichi, M., Yudai, F., Takeshi, K., Atsushi, O., Shun, K., Satoshi, S., S, C.E., Jonathan, C., J, M.R., & A, G.N. (2026). Bridging the Divide: Divergent Diagnostic Philosophies and Practice Pathways for Cardiac Sarcoidosis between Japan and North America.. Journal of cardiac failure.
Yuya M, Daichi M, Yudai F, Takeshi K, Atsushi O, Shun K, et al. Bridging the Divide: Divergent Diagnostic Philosophies and Practice Pathways for Cardiac Sarcoidosis between Japan and North America.. Journal of cardiac failure. 2026; PMID: 42114735
Yuya M, Daichi M, Yudai F, et al. Bridging the Divide: Divergent Diagnostic Philosophies and Practice Pathways for Cardiac Sarcoidosis between Japan and North America.[J]. Journal of cardiac failure. 2026.
@article{yuya2026,
author = {Matsue Yuya and Maeda Daichi and Fujimoto Yudai and Kitai Takeshi and Okada Atsushi and Kohsaka Shun and Shoji Satoshi and Chen Edward S and Chrispin Jonathan and Mentz Robert J and Gilotra Nisha A},
title = {Bridging the Divide: Divergent Diagnostic Philosophies and Practice Pathways for Cardiac Sarcoidosis between Japan and North America.},
journal = {Journal of cardiac failure},
year = {2026},
note = {PMID: 42114735},
}
TY - JOUR AU - Matsue Yuya AU - Maeda Daichi AU - Fujimoto Yudai AU - Kitai Takeshi AU - Okada Atsushi AU - Kohsaka Shun AU - Shoji Satoshi AU - Chen Edward S AU - Chrispin Jonathan AU - Mentz Robert J AU - Gilotra Nisha A TI - Bridging the Divide: Divergent Diagnostic Philosophies and Practice Pathways for Cardiac Sarcoidosis between Japan and North America. T2 - Journal of cardiac failure PY - 2026 AN - PMID:42114735 ER -
Cardiac sarcoidosis (CS) is an increasingly recognized inflammatory cardiomyopathy that can present with ventricular arrhythmias and progressive heart failure (HF). Despite advances in various imaging modalities, notable regional differences persist in how CS is suspected, diagnosed, and managed. In Japan, where CS has long been a clinical priority and advanced imaging is widely accessible, screening and diagnostic pathways are often applied earlier in the disease course. In contrast, in many North American and Western settings, CS is frequently identified after presentation with advanced cardiomyopathy or arrhythmic complications. The most profound divergence lies in the diagnostic framework. The Japanese Circulation Society (JCS) guidelines emphasize early recognition of clinically diagnosed forms for cardiac involvement in patients with known systemic sarcoidosis without the requirement of invasive endomyocardial biopsy. The JCS guidelines also formally recognize "clinically isolated CS" as a clinically defined entity confined to the heart. In contrast, the US criteria prioritize specificity, requiring histological proof from any organ for a definitive diagnosis. This divergence propagates downstream discrepancies in risk stratification and therapeutic strategies. In this review, we discuss the original research underpinning these frameworks, and the need for international harmonized research efforts to better define this entity and inform future diagnostic and management strategies.